Phenotyping of epidermal dendritic cells: Clinical applications of a flow cytometric micromethod
β Scribed by Andreas Wollenberg; Songping Wen; Thomas Bieber
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 232 KB
- Volume
- 37
- Category
- Article
- ISSN
- 0196-4763
No coin nor oath required. For personal study only.
β¦ Synopsis
Background:
The differential diagnosis of inflammatory skin diseases is largely based on the patient's history and the morphological analysis of the skin lesion. Laboratory data, such as serum IgE-level and prick and patch tests, may be helpful but do not assess individual lesions. The assumption of our approach is that each individual lesion is associated with a specific microenvironment and that the immunophenotype of the two epidermal dendritic cell populations, Langerhans cells (LC) and inflammatory dendritic epidermal cells (IDEC), reflects this environment in a disease-specific manner. Methods: A flow cytometric micromethod was developed to directly analyze individual inflammatory human skin lesions. Crude epidermal single cell suspensions were prepared by trypsinization, stained for three-color analysis with different monoclonal antibodies and the vital stain 7-amino-actinomycin-D, and finally analyzed on a single laser equipped FACScan flow cytometer. Results: With a limited set of cell surface markers, such as FcβRI, Fcβ₯RII/CD32, CD1b and CD36, highly specific diagnostic criteria for atopic dermatitis and inflamed human skin could be established. Conclusions: Phenotyping of epidermal dendritic cells is a useful procedure helpful in differential diagnosis of inflammatory skin diseases.
π SIMILAR VOLUMES
## Abstract ## Background Flow cytometric analysis of peripheral blood dendritic cells (PBDCs) and their myeloid (mDCs) and plasmacytoid (pDCs) subsets is a less invasive procedure that is acquiring growing clinical relevance. Because dendritic cells (DCs) lack unique lineage markers, current meth
Blood dendritic cells (DCs) may be identified as mononuclear leucocytes with high expression of HLA-DR, but lacking the antigens CD3, CD14, CD16, CD19, and CD56, which are characteristically expressed by T cell, monocytes, B cells, and natural killer cells. However, some DCs have recently been repor
Dendritic cells (DC) used for clinical trials should be processed on a large scale conforming to current good manufacturing practice (cGMP) guidelines. The aim of this study was to develop a protocol for clinical grade generation of immature DC in a closed-system. Aphereses were performed with the C